- Home
- CPRI vs ELVN Comparison
CPRI vs ELVN Comparison
Compare CPRI & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CPRI | ELVN |
|---|---|---|
| Founded | 1981 | 2016 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.6B |
| IPO Year | 2011 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CPRI | ELVN |
|---|---|---|
| Price | $18.27 | $35.52 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 5 |
| Target Price | $26.62 | ★ $43.40 |
| AVG Volume (30 Days) | ★ 3.2M | 568.3K |
| Earning Date | 05-27-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 111.40 | 3.17 |
| EPS | ★ 1.14 | N/A |
| Revenue | ★ $3,474,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.81 | N/A |
| P/E Ratio | $16.14 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $16.49 | $14.79 |
| 52 Week High | $28.27 | $48.53 |
Technical Indicators
Market Signals| Indicator | CPRI | ELVN |
|---|---|---|
| Relative Strength Index (RSI) | 47.27 | 34.78 |
| Support Level | $16.82 | $19.19 |
| Resistance Level | $22.24 | $44.09 |
| Average True Range (ATR) | 0.89 | 2.13 |
| MACD | 0.11 | -0.64 |
| Stochastic Oscillator | 41.86 | 5.47 |
Price Performance
Historical ComparisonAbout CPRI Capri Holdings Limited
Capri Holdings is a marketer, distributor, and retailer of upscale accessories and apparel in the Americas, Europe, and Asia. Michael Kors, Capri's original and largest brand by sales, offers handbags, footwear, and apparel through more than 700 company-owned stores, wholesale, and e-commerce. Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. Its products are sold in more than 200 company-operated stores. John Idol has served as Capri's CEO since 2003.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.